Share chart Eloxx Pharmaceuticals, Inc.
Extended chart
Simple chart
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., биофармацевтическая компания клинической стадии, занимается разработкой модуляции рибосом для лечения редких и ультраредких преждевременных заболеваний стоп-кодонов. Его ведущим кандидатом в исследуемый лекарственный продукт является ELX-02, который находится на стадии 2 клинических испытаний для лечения пациентов с муковисцидозом и нефропатическим цистинозом с диагностированными нонсенс-мутациями. more details| IPO date | 2018-01-19 |
|---|---|
| ISIN | US29014R1032 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.eloxxpharma.com |
| Цена ао | 0.0001 |
| Change price per day: | 0% (0.0001) |
|---|---|
| Change price per week: | 0% (0.0001) |
| Change price per month: | 0% (0.0001) |
| Change price per 3 month: | -50% (0.0002) |
| Change price per half year: | -99.99% (0.7) |
| Change price per year: | -99.99% (0.853) |
| Change price per 3 year: | -99.98% (0.45) |
| Change price per 5 year: | -100% (6.94) |
| Change price per 10 year: | 0% (0.0001) |
| Change price per year to date: | 0% (0.0001) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Armistice Capital, LLC | 275000 | 8.75 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 54075 | 1.72 |
| Menora Mivtachim Holdings Ltd. | 52355 | 1.67 |
| American Financial Group Inc. | 37000 | 1.18 |
| Altshuler Shaham Ltd | 25123 | 0.8 |
| Vanguard Group Inc | 20786 | 0.66 |
| Geode Capital Management, LLC | 19588 | 0.62 |
| Clal Insurance Enterprises Holdings Ltd | 13526 | 0.43 |
| Atom Investors LP | 10638 | 0.34 |
| Blackrock Inc. | 8870 | 0.28 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Sumit Aggarwal M.B.A. | President, CEO & Director | 839.67k | 1973 (52 years) |
| Ms. Barbara Ryan | Investor Relations Officer | N/A | |
| Dr. Ali Hariri M.D. | Chief Medical Officer | N/A | |
| Mr. Daniel E. Geffken M.B.A. | Interim CFO, Principal Financial Officer & Principal Accounting Officer | 63.96k | 1957 (68 years) |
Address: United States, Watertown. MA, 480 Arsenal Way - open in Google maps, open in Yandex maps
Website: https://www.eloxxpharma.com
Website: https://www.eloxxpharma.com
